{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:09:55Z","timestamp":1780751395654,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1981,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031829","name":"Ceva Sante Animale","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031829","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ceva Sante Animale"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Torasemide is a potent loop diuretic with potential to treat congestive heart failure (CHF) in dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Evaluate the efficacy and safety of torasemide compared to furosemide in dogs with first occurrence of CHF caused by degenerative mitral valve disease (DMVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Three hundred and nineteen dogs with new onset CHF attributable to DMVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Double-blinded randomized noninferiority study of PO torasemide vs furosemide in addition to standard CHF treatment. The primary efficacy criterion was decreased pulmonary edema and cough and no worsening of dyspnea or exercise tolerance at day 14. Secondary endpoints included clinical response at day 84 and time to death, euthanasia, or premature study withdrawal for cardiac reasons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Torasemide q24h (n = 161) was noninferior to furosemide q12h (n = 158); percentage of dogs meeting primary efficacy criterion at day 14 was similar between groups (torasemide, 74.4% [95% confidence interval (CI), 66.8%-81.0%] vs. furosemide, 73.5% [95% CI, 65.7%-80.4%]; risk ratio [RR], 1.01; 95% CI, 0.89-1.15; P = .87). Efficacy at day 84 showed similar results (RR, 1.05; 95% CI, 0.88-1.25; P = .6). Dogs receiving torasemide had a longer time to endpoint and were less than half as likely to experience death, euthanasia, or premature study withdrawal (hazard ratio, 0.36; 95% CI, 0.19-0.65; P = .001) than dogs receiving furosemide at any time during the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Clinical importance<\/jats:title>\n                    <jats:p>Torasemide was noninferior to furosemide as first line PO treatment for new onset CHF caused by DMVD. Torasemide significantly decreased risk of cardiac-related death or premature study withdrawal for cardiac reasons compared to furosemide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.15864","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T15:16:31Z","timestamp":1596813391000},"page":"1746-1758","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study"],"prefix":"10.1093","volume":"34","author":[{"given":"Beatrice","family":"Besche","sequence":"first","affiliation":[{"name":"Ceva Sant\u00e9 Animale , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Blondel","sequence":"additional","affiliation":[{"name":"Ceva Sant\u00e9 Animale , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Guillot","sequence":"additional","affiliation":[{"name":"Ceva Sant\u00e9 Animale , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Garelli-Paar","sequence":"additional","affiliation":[{"name":"Ceva Sant\u00e9 Animale , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5218-9226","authenticated-orcid":false,"given":"Mark A.","family":"Oyama","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of Pennsylvania Department of Clinical Sciences and Advanced Medicine, , Philadelphia, Pennsylvania,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2026020922092240500_jvim15864-bib-0001","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/jvim.15488","article-title":"ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs","volume":"33","author":"Keene","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020922092240500_jvim15864-bib-0002","first-page":"144","article-title":"Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide","volume":"38","author":"Delarge","year":"1988","journal-title":"Arzneimittelforschung"},{"key":"2026020922092240500_jvim15864-bib-0003","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1292\/jvms.65.1057","article-title":"The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats","volume":"65","author":"Uechi","year":"2003","journal-title":"J Vet Med Sci"},{"key":"2026020922092240500_jvim15864-bib-0004","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.2042-7158.1996.tb05936.x","article-title":"Urinary excretion profile of torasemide and its diuretic action in dogs","volume":"48","author":"Sogame","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"2026020922092240500_jvim15864-bib-0005","first-page":"293","article-title":"Diuretic profile of a novel loop diuretic torasemide in rats and dogs","volume":"17","author":"Uchida","year":"1991","journal-title":"Drugs Exp Clin Res"},{"key":"2026020922092240500_jvim15864-bib-0006","first-page":"1520","article-title":"Pharmacological properties of the new potent diuretic torasemide in rats and dogs","volume":"35","author":"Ghys","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"2026020922092240500_jvim15864-bib-0007","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/jvp.12316","article-title":"A pharmacokinetic\/pharmacodynamic model capturing the time course of torasemide-induced diuresis in the dog","volume":"39","author":"Paulin","year":"2016","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020922092240500_jvim15864-bib-0008","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2459\/JCM.0000000000000794","article-title":"Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis","volume":"20","author":"Miles","year":"2019","journal-title":"J Cardiovasc Med"},{"key":"2026020922092240500_jvim15864-bib-0009","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.ejim.2018.08.015","article-title":"Torsemide versus furosemide in heart failure patients: a meta-analysis of randomized controlled trials","volume":"57","author":"Shah","year":"2018","journal-title":"Eur J Intern Med"},{"key":"2026020922092240500_jvim15864-bib-0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: results of the TORIC study","volume":"4","author":"Cosin","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"2026020922092240500_jvim15864-bib-0011","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jvc.2012.01.003","article-title":"Effect of torsemide and furosemide on clinical, laboratory, radiographic and quality of life variables in dogs with heart failure secondary to mitral valve disease","volume":"14","author":"Peddle","year":"2012","journal-title":"J Vet Cardiol"},{"key":"2026020922092240500_jvim15864-bib-0012","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jvc.2011.10.001","article-title":"Use of the loop diuretic torsemide in three dogs with advanced heart failure","volume":"13","author":"Oyama","year":"2011","journal-title":"J Vet Cardiol"},{"key":"2026020922092240500_jvim15864-bib-0013","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/vr.160.24.847","article-title":"Effect of torsemide on serum and urine electrolyte levels in dogs with congestive heart failure","volume":"160","author":"Caro-Vadillo","year":"2007","journal-title":"Vet Rec"},{"key":"2026020922092240500_jvim15864-bib-0014","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/jvim.14841","article-title":"Short-term efficacy and safety of torasemide and furosemide in 366 dogs with degenerative mitral valve disease: the TEST study","volume":"31","author":"Chetboul","year":"2017","journal-title":"J Vet Intern Med"},{"key":"2026020922092240500_jvim15864-bib-0015","first-page":"883","article-title":"Textbook of Canine and Feline Cardiology","author":"Council ISACH","year":"1999","edition":"2"},{"key":"2026020922092240500_jvim15864-bib-0016","author":"European Medicines Agency-Committee for Medicinal Products for Veterinary Use (CVMP)"},{"key":"2026020922092240500_jvim15864-bib-0017","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fvets.2020.00151","article-title":"Population pharmacokinetics and pharmacodynamics modeling of torasemide and furosemide after oral repeated administratin in healthy dogs","volume":"7","author":"Pelligand","year":"2020","journal-title":"Front Vet Sci"},{"key":"2026020922092240500_jvim15864-bib-0018","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2460\/javma.2005.226.1864","article-title":"Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease","volume":"226","author":"Freeman","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922092240500_jvim15864-bib-0019","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2460\/javma.1995.206.02.194","article-title":"Vertebral scale system to measure canine heart size in radiographs","volume":"206","author":"Buchanan","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020922092240500_jvim15864-bib-0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1939-1676.2004.tb02551.x","article-title":"Allometric scaling of M-mode cardiac measurements in normal adult dogs","volume":"18","author":"Cornell","year":"2004","journal-title":"J Vet Intern Med"},{"key":"2026020922092240500_jvim15864-bib-0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1745-6215-12-106","article-title":"Through the looking glass: understanding non-inferiority","volume":"12","author":"Schumi","year":"2011","journal-title":"Trials"},{"key":"2026020922092240500_jvim15864-bib-0022","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.amjcard.2015.10.059","article-title":"Torsemide versus furosemide in patients with acute heart failure (from the ASCEND-HF trial)","volume":"117","author":"Mentz","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026020922092240500_jvim15864-bib-0023","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2019.01.109","article-title":"Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - a multicenter propensity score matched analysis","volume":"289","author":"Tager","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026020922092240500_jvim15864-bib-0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10557-018-6843-5","article-title":"Comparative analysis of long-term outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiology","volume":"33","author":"Ozieranski","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026020922092240500_jvim15864-bib-0025","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2217\/fca.15.56","article-title":"Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial","volume":"11","author":"Mentz","year":"2015","journal-title":"Future Cardiol"},{"issue":"5","key":"2026020922092240500_jvim15864-bib-0026","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.japh.2019.01.014","article-title":"Comparing torsemide versus furosemide in patients with heart failure: a meta-analysis","volume":"59","author":"Kido","year":"2019","journal-title":"J Am Pharm Assoc"},{"key":"2026020922092240500_jvim15864-bib-0027","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1388-9842(03)00150-8","article-title":"Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV\u2013efficacy and quality of life","volume":"5","author":"Muller","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"2026020922092240500_jvim15864-bib-0028","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ahj.2014.12.009","article-title":"A reappraisal of loop diuretic choice in heart failure patients","volume":"169","author":"Buggey","year":"2015","journal-title":"Am Heart J"},{"key":"2026020922092240500_jvim15864-bib-0029","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026020922092240500_jvim15864-bib-0030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0009-9236(95)90222-8","article-title":"Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure","volume":"57","author":"Vargo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"2026020922092240500_jvim15864-bib-0031","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/FJC.0000000000000212","article-title":"Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital","volume":"65","author":"Mentz","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026020922092240500_jvim15864-bib-0032","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ejhf.757","article-title":"Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure","volume":"19","author":"Ter Maaten","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026020922092240500_jvim15864-bib-0033","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1748-5827.2011.01094.x","article-title":"Promoting discussions and decisions about dogs\u2019 quality-of-life","volume":"52","author":"Yeates","year":"2011","journal-title":"J Small Anim Pract"},{"key":"2026020922092240500_jvim15864-bib-0034","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.tvjl.2015.07.016","article-title":"Quality of life assessment in domestic dogs: an evidence-based rapid review","volume":"206","author":"Belshaw","year":"2015","journal-title":"Vet J"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.15864","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.15864","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.15864","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/5\/1746\/66661554\/jvim15864.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/34\/5\/1746\/66661554\/jvim15864.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T03:17:18Z","timestamp":1770693438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/34\/5\/1746\/8448428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.15864","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"2019-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}